Patent ID: 9545382
Date: 2017-01-17
CPC Classifications: A61K

Claim:
1. A method of treating a patient for hepatocellular carcinoma with a formulation comprising therapeutic agents comprising: a. forming a first solution of doxorubicin comprising one or more proteins or polymers; b. conjugating sorafenib with an active targeting ligand with one or more proteins to form a second solution; c. producing a formulation comprising nanoparticles using the first and the second solutions; and d. administering the nanoparticle formulation to a patient such that the targeting ligand causes the formulation to preferentially segregate to the hepatocellular carcinoma tissue to release the therapeutic agents; wherein the nanoparticles comprise polyvinyl alcohol forming a core and human serum albumin forming a shell; wherein the doxorubicin and the sorafenib are loaded onto the same nanoparticle such that doxorubicin is loaded onto the core and sorafenib is loaded onto the shell; wherein the ligand for targeting comprises transferrin; and wherein the formulation is administered by intraarterial delivery.